Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, a8 integrin. HC11 cells derived from normal mammary epithelium do not express a8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express a8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-b1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38 MAPK and JNK signaling pathways. Since preinflammatory cytokines also act through p38 MAPK and JNK signaling pathways, the possible role of TNF-a in tenascin-W expression was also examined. TNF-a induced the expression of both tenascin-W and tenascin-C, and this induction was p38 MAPK -and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.
Introduction
Extracellular matrix (ECM) not only provides a physical support to maintain normal tissue architecture but also regulates aspects of cell migration, growth, differentiation and survival. The tenascins are a family of ECM glycoproteins typically present in different connective tissues. Tenascins contribute to matrix structure and they influence the behavior of the cells in contact with the ECM (for reviews see Jones and Jones, 2000; Chiquet-Ehrismann and Chiquet, 2003; Chiquet-Ehrismann, 2004) . In vertebrates the tenascin family is composed of four members: tenascin-C (TN-C), tenascin-R, tenascin-X (TN-X) and the most recently characterized member tenascin-W (TN-W) described in zebrafish (Weber et al., 1998) and mouse (Scherberich et al., 2004 ; also referred to as tenascin-N in Neidhardt et al., 2003) . Searches of the genomic databases using sequence homologies indicate that TN-W is most likely the final member of the tenascin family.
In a previous study we cloned and characterized the murine TN-W (Scherberich et al., 2004) . Rotary shadowing followed by electron microscopy showed that like TN-C, TN-W forms hexabrachions. During development TN-W is expressed during palate formation, osteogenesis and smooth muscle morphogenesis. In the adult, TN-W is found in the kidney, coronary ligament, corneal limbus and periosteum. TN-W and TN-C expression overlap in many of these areas. Bone morphogenic protein (BMP)-2 treated C2C12 cells secrete TN-W and are able to adhere to and to extend actin-rich processes on a TN-W substratum. In vitro, cells bind to TN-W in an RGD-dependent manner. This adhesion is increased by transfection of a8 integrin, which co-localizes with TN-W in the periosteum and kidney. The presence of the tenascins mainly in connective tissues suggests that they contribute to ECM structure This is particularly clear for TN-X where patients with TN-X deficiencies suffer from an Ehlers Danlos phenotype with abnormalities of the elastic fibers and microfibrils in the dermis and a reduced dermal collagen content (Zweers et al., 2004) .
TN-C and TN-X have been reported to be involved in general tumor malignancy (Mackie et al., 1987; Hasegawa et al., 1997; Chiquet-Ehrismann and Chiquet, 2003) . Several lines of evidence have emphasized a role for TN-C in breast cancer. In invasive mammary carcinomas, for example, TN-C expression correlates with lymph node status and tumor grade, and represents a good marker for negative prognostic value (Ioachim et al., 2002) . In ductal carcinomas, large variants of TN-C correlate with the invasive phenotype of breast lesions (Adams et al., 2002; Tsunoda et al., 2003) , and inversely correlate with the expression of the metastasis suppressor nm23-H1 (Kaya et al., 2002) . In noninvasive and invasive ductal cancers, adenoses and fibroadenomas, TN-C is suitable for diagnosis of malignant disease and for the prediction of invasive potential of premalignant lesions (Goepel et al., 2000) . In contrast, the expression of TN-X is downregulated in astrocytomas (Hasegawa et al., 1997) and malignant melanomas (Geffrotin et al., 2000) as the grade of malignancy progresses.
Here we studied the potential involvement of TN-W in mammary tumor formation and metastatic spreading. The expression of TN-W and its putative receptor a8 integrin was investigated in mammary tissues derived from transgenic mouse models with primary tumors of varying metastatic potential. In addition, we studied the role of TN-W in the migration and proliferation of murine mammary cell lines, as well as signal pathways relevant to breast cancer that govern the induction of TN-W in vitro. Our results show that TN-W may contribute to tumor metastasis, and that TN-W may prove to be a useful diagnostic marker.
Results

Expression of TN-W and alpha8 integrin in mammary tumors
To investigate the potential role of TN-W in breast cancer, we took advantage of well-characterized mouse mammary tumor models of transgenic mice transformed with the oncogenes c-myc, neuT (the rat homologue of c-erbB2), Ha-ras or from double transformations of neuT/EphB4 under MMTV-LTR or the mammary gland-specific promoter of whey acidic protein (Wap; Andres et al., 1987; Schoenenberger et al., 1988; Munarini et al., 2002) . Immunohistochemistry with anti-TN-W and anti-TN-C antibodies was performed on frozen sections from mouse mammary glands. Immunoreactivity with the anti-TN-W antibody was not detected in the normal mammary glands of nontransgenic mice (data not shown). Similarly, no immunostaining for TN-W was found in mammary tumors from MMTV-neuT-and Wap-myc-transgenic mice (Figure 1 ). MMTV-neuT transgenic mice are known to develop isolated primary tumors but do not develop lung metastases (Munarini et al., 2002) . Similarly, mice expressing the Wap-myc transgene develop well-differentiated, nonmetastatic breast tumors after several pregnancies . In Wapras-and MMTV-neuT/EphB4-transformed mice, which are known to develop undifferentiated, metastatic tumors (Li et al., 1994; Munarini et al., 2002) , the tumor stroma was positive for TN-W (Figure 1 ).
In contrast to the restricted labeling seen with anti-TN-W, staining with anti-TN-C was observed in all of the mammary tumors tested ( Figure 1 ). As illustrated in the staining overlay (Figure 1 ), TN-W was often, but not always, co-localized with TN-C in the tumor stroma of the TN-W positive samples.
To confirm the induction of TN-W in tumors with the potential to metastasize, the expression of TN-W was further investigated by Western blot analysis of a larger series of samples. In normal mammary glands from virgin, pregnant or lactating mice, TN-W was not detectable by Western blotting (Table 1 ). Only two of the 15 different tumors isolated from mice expressing the MMTV-neuT-or Wap-myc-transgenes expressed detectable levels of TN-W. In contrast, TN-W expression was detected in 75% (12 of 16) of the Wap-ras-and MMTV-neuT/EphB4-induced mammary tumors.
Since a8 integrin was shown previously to serve as a potential receptor for TN-W, and often co-localized with TN-W (Scherberich et al., 2004) , we performed a Western blot analysis of the same samples with an antia8 integrin antibody (Table 1) . Normal mammary gland samples showed little or no expression of a8 integrin. Samples from MMTV-neuT-and Wap-myc-transgenic mice were negative as well, with the exception of a single MMTV-neuT sample. In samples from tumors with high metastatic potential, a strong induction of a8 integrin was observed except for Wap-ras-induced tumors where only a third of the samples were positive for a8 integrin. The localization of a8 integrin expression was then investigated by immunohistochemistry. a8 integrin immunostaining was absent from normal mammary gland ( Figure 2a ) but was seen in mammary tumors (Figure 2b ). The expression was stronger at the periphery of the tumor and was absent in the normal tissue around the tumor. Figure 2c and d show that a8 integrin expression was prominent in the cells adjacent to the tumor stroma. We conclude that the chance to find a8 integrin expressing cancer cells surrounded by TN-W-positive tumor stroma increases in more malignant tumors.
TN-W promotes migration of mammary cancer cells
Since TN-W is present in the stroma surrounding some metastatic mammary cancers, it is important to investigate the effects TN-W might have on the neighboring cancer cells. Since TN-C was shown previously to promote the proliferation of tumor cells in vitro ), a similar study was conducted with TN-W. In contrast to TN-C, TN-W had no effect on tumor cell proliferation (results not shown). Next, we investigated the effect of TN-W on the migration of mammary cells using a modified Boyden chamber migration assay. We compared the behavior of the normal mammary epithelial cell line HC11 to 4T1 mammary cancer cells. HC11 cells readily migrated across a filter coated with fibronectin, migrated slightly on type-I collagen, but failed to migrate across filters coated with either TN-W or TN-C (Figure 3a) . Interestingly, the migration of 4T1 cells across the filter was stimulated by fibronectin, type-I collagen and TN-W, but not TN-C (Figure 3b) . A possible explanation for the different behavior of these cells on TN-W-coated filters would be the expression of a8 integrin by 4T1 cells but not HC11 cells. This hypothesis was confirmed by Western blot analysis ( Figure 3c ). To demonstrate that the expression of a8 integrin is sufficient to promote adhesion to TN-W and migration across TN-W-coated filters, the ability of NIH/3T3 cells transfected with an expression vector encoding full-length a8 integrin to cross coated filters was compared with the behavior of cells transfected with the empty vector alone. Note that NIH/3T3 cells were selected for this experiment because of extremely low transfection efficiency encountered with HC11 cells and because we could not detect endogenous a8 integrin expression by Western blotting. Significantly more NIH/ 3T3 cells transfected with the a8 integrin expression vector adhered in short-term adhesion assays to TN-W coated dishes than control cells (Figure 3d ). The same was true in migration assays. Vector only transfected cells do not migrate differently from control cells on bovine serum albumin (BSA) and TN-C-coated filters but a8 integrin overexpressing cells were stimulated to cross TN-W-coated filters (Figure 3e ). Thus, TN-W in breast cancer stroma might contribute to the migratory behavior of tumor cells expressing a8 integrin.
BMP-2 induces the expression of TN-W in vitro
We have previously shown that BMP-2 can induce the expression of TN-W in C2C12 cells (Scherberich et al., 2004) . Here we show that primary mouse embryo fibroblasts also release high amounts of TN-W when stimulated by 100 or 200 ng/ml BMP-2 when compared with control, unstimulated cells (Figure 4a, upper blot) . TGF-b1 was tested as well but failed to induce TN-W expression strongly, even at doses up to 50 ng/ml. The Table 1 Expression of tenascin-W and a8 integrin in mouse mammary samples
Approximately equal volumes of normal and tumor-containing mammary tissue samples dissected from control and transgenic mice were solubilized in SDS-PAGE sample buffer and subjected to a Western blot analysis with either anti-mouse TN-W or anti-mouse a8 integrin. For each sample, the positive or negative staining was determined and the results pooled by category. The percentage of samples with positive and negative staining is shown, as well as the number of samples in each category. For a8 integrin, a very faint band was sometimes present (+) but was considered with the negative samples, given the fact that positive bands (++) were much stronger (Figure 4a , lower blot). TN-C was strongly induced by TGF-b1, but its expression was induced to a lesser extent by BMP-2. Thus, BMP-2 not only induces TN-W expression in in vitro models of bone differentiation (Scherberich et al., 2004) but also in primary mouse fibroblasts. TN-C is regulated differently in these cells, and is particularly responsive to TGF-b1. We used embryonic fibroblasts as a model for the tumor stromal fibroblasts that are the source of TN-W in cancer. 4T1 mammary carcinoma cells themselves did not respond with TN-W production after BMP2 nor TGF-b1 addition (Figure 4b ). In contrast, HC11 normal mammary epithelial cells could be stimulated to secrete TN-W after the addition of BMP2 (Figure 4b ). To test the relevance of an induction of TN-W by BMP-2 in mammary cancer in vivo, we tested by Western blotting the expression of BMP-2 in homogenates of the normal and tumor samples described in Table 1 (Gallea et al., 2001; Vinals et al., 2002; Guicheux et al., 2003) . We therefore considered the potential involvement of p38 MAPK and JNK in the regulation of TN-W expression. In the absence of BMP-2 stimulation, 10 mg/ml of a selective p38 MAPK inhibitor (SB203580) reduced the endogenous expression of TN-W in primary mouse embryo fibroblasts (Figure 4c, upper panel) . The expression of TN-C in these cells was not modified by this inhibitor (Figure 4c , lower panel). The same result was obtained with another p38 MAPK inhibitor SB202190 (not shown). In contrast, an inhibitor of the ERK pathway (U-0126) had no effect on either TN-W or TN-C expression (Figure 4c ). To show a role of p38 MAPK in TN-W induction by BMP-2, SB203580 was added with BMP-2 to the cells. SB203580 inhibited the induction, as seen in Figure 4d . SP600125, an inhibitor of JNK, also reduced the expression of TN-W in primary mouse embryonic fibroblasts, but had no effect on TN-C expression (Figure 4e ).
TNF-a induces TN-W expression in vitro
As the endogenous as well as the BMP-2 induced expression of TN-W by mouse embryo fibroblasts depend upon p38 MAPK activity (see above), which are known to be triggered by various cytokines, we tested whether TNF-a could also induce the expression of TN-W. TNF-a stimulated the expression of both TN-W Tenascin-W in breast cancer A Scherberich et al and TN-C in primary mouse embryo fibroblasts (Figure 5a ). Both the TNF-a-induced and the endogenous expression of TN-W by primary mouse embryo fibroblasts were inhibited by the specific inhibitor of p38 MAPK SB202190 (Figure 5b) , and by SB203580 (not shown). Finally, we showed that indomethacin, a nonspecific inhibitor of cyclooxygenases (COX), also inhibited the endogenous and TNF-a-induced expression of TN-W by primary mouse fibroblasts (Figure 5c ). Thus, inflammatory cytokines are likely candidates responsible for the induction of TN-W in mammary tumors.
Discussion
Here we have characterized the potential role of TN-W in the development of mammary cancer. We found that this protein is more widely expressed in the mammary tumors of the mice known to develop metastases than in nonmetastatic tumors. Unlike TN-C, TN-W was not detected in normal mammary tissues. a8 integrin, which was previously shown to be a likely receptor for TN-W (Scherberich et al., 2004) , was also mostly absent from healthy mammary tissue and in nonmetastatic tumors, but showed increased expression in the primary tumors with the greatest potential to metastasize. There is only one previous report showing an upregulation of a8 integrin in human tumors (Liu et al., 2002) . In our study we show that the likelihood of stromal TN-W expression increases with the malignancy of a tumor and the incident of a8 integrin expression in the cancer cells themselves is also increased. Therefore, co-expression of these two proteins is more likely in malignant tumors. We postulate that if such a co-expression occurs the tumor cells are enabled to invade the TN-W expressing stoma. Such a mechanism is supported by our in vitro experiments. We found that TN-W can support the migration of breast cancer cells in vitro, but is not a favorable substratum for the migration of a cell line derived from normal mammary epithelium. This difference may be due to the expression of a8 integrin by the former but not the latter. Further support for a role of a8 integrin in cell adhesion to and migration on TN-W was obtained from 3T3 cells transfected with an a8 expression construct. Overexpression of a8 integrin increased cell adhesion to TN-W and promoted cell migration towards TN-W. We hypothesize that the presence of TN-W in the stroma of the tumor may help metastasizing cells that express a8 integrin to leave the tumor and invade the surrounding tissue. Unlike TN-C, which can stimulate the proliferation of tumor cells by blocking fibronectin-mediated adhesion signaling , TN-W does not have a significant effect on 4T1 cells in a proliferation assay.
In order to determine the mechanisms by which TN-W expression is induced in tumor tissue, we investigated how TN-W expression is regulated in cultured cells. We have shown in a previous report that BMP-2 is able to induce the expression of TN-W in C2C12 cells (Scherberich et al., 2004) . BMP-2 and other members of the BMP family (Schwalbe et al., 2003) are interesting candidates for TN-W induction since they are known to be expressed in breast cancer cell lines and tumor samples (Clement et al., 1999; Pouliot et al., 2003) . We confirmed here that BMP-2 is present in some but not all of the murine mammary tumors that also express TN-W. BMP-2, but not TGF-b1, could indeed induce the expression of TN-W in primary mouse embryo fibroblasts. Interestingly, just the opposite was observed for TN-C, which was induced by TGF-b1, but not BMP-2. The fact that TN-C and TN-W are independently regulated by TGF-b1 and BMP-2 could partly explain why they are not always co-localized during development (Scherberich et al., 2004) .
Recently, several studies have shown that BMP-2 can activate p38 MAPK and JNK, but not ERK/MAPK, in osteoblasts (Vinals et al., 2002; Guicheux et al., 2003) , by a mechanism which is still largely unknown (Lemonnier et al., 2004) . We therefore investigated the importance of these pathways on the endogenous expression of TN-W in fibroblasts and showed that the inhibition of p38 MAPK or JNK dramatically inhibited the expression of TN-W, whereas an inhibitor of ERK/ MAPK had no effect. None of these inhibitors affected the expression of TN-C. The role of p38 MAPK in the regulation of TN-W expression is particularly interesting since it was shown to be a promising potential target in the treatment of cancer (reviewed in Schultz, 2003) . Activated p38 MAPK appears to be expressed in a constitutive manner in a broad range of cancers including breast carcinoma (Chen et al., 2001; Xiong et al., 2001; Salh et al., 2002) . We thus hypothesize that this activation of p38
MAPK results, at least in part, in the induction of TN-W expression.
Several studies suggest that proinflammatory cytokines such as TNF-a and IL-1b have activities that contribute to metastatic tumor spread. For example, transfection of TNF-a in tumor cells confers a metastatic phenotype (Malik et al., 1990; Qin et al., 1993) and antibody neutralization of endogenous tumor-induced TNF-a leads to a significant decrease in the number of pulmonary metastases (Qin et al., 1993) . Moreover, human clinical studies have similarly associated increased levels of TNF-a with metastatic disease (Ocvirk et al., 2000; Michalaki et al., 2004) . Here we show that TNF-a is capable of inducing TN-W in vitro, and that its induction is dependent on p38 MAPK and COX pathways. Thus, inflammatory cytokines including TNF-a are likely candidate molecules to induce TN-W expression in tumor stroma. The involvment of p38 MAPK in TNF-a signaling is in contrast to a previous report on TNF-a induction of TN-C in keratinocytes, where the signal was dependent on JNK (Latijnhouwers et al., 1998) .
TN-C is a useful prognostic marker of a number of types of tumors and appears to play a role in tumor metastasis. Here we show in a mouse breast cancer model that a recently discovered member of the tenascin family, TN-W, is more restricted in its expression than TN-C to tumors with the greatest potential to metastasize. TN-W can promote the motility of cells expressing a8 integrin, and this may contribute to the invasive spread of cancers. These observations point to future studies on the use of TN-W as a diagnostic tool as well as a potential target for cancer therapy.
Materials and methods
Antibodies and reagents
The rabbit polyclonal antibody to TN-W was developed in our laboratory and described previously (Scherberich et al., 2004) . The rabbit polyclonal anti-a8 integrin antibody B11 was a generous gift from Dr U Mu¨ller (Basel, Switzerland). The mouse monoclonal antibody against BMP-2 was purchased from Santa Cruz Biotechnology. Recombinant human BMP-2 and mouse TNF-a, the rat monoclonal anti-TN-C antibody MTn-12, and the indomethacin were all from Sigma. Human TGF-b1 was purchased from R&D Systems. SB203580 and SP600125 were kindly provided by Dr Y Nagamine (Basel, Switzerland), and U-0126 was a gift from Dr V Biou (Basel, Switzerland). SB202190 was obtained from Sigma.
Cell culture
Primary mouse embryonic fibroblasts were kindly provided by Patrick Kopp (Basel, Switzerland), and cultured with DME medium supplemented with 10% fetal calf serum (FCS). The HC11 normal mouse mammary epithelial cells were provided by Dr N Hynes (Basel, Switzerland). They were cultured in RPMI 1640 medium supplemented with 10% FCS, 5 mg/ml insulin and 10 ng/ml EGF (Hynes et al., 1990) . The 4T1 invasive mouse mammary tumor cells (CRL-2539) and the NIH/3T3 cells (CRL-1658) were obtained from The American Type Culture Collection and cultured in DME with 10% FCS.
Tumor samples
For protein analysis, mammary tissues from the different transgenic mice were removed, snap frozen in liquid nitrogen and stored at À701C. For histochemistry mammary tissues were fixed, frozen and cryosectioned at 5 mm. The transgenic Wap-myc and Wap-ras mice have been described in detail previously (Andres et al., 1987 Schoenenberger et al., 1988) , as have the transgenic neu-T and EphB4 mice (Munarini et al., 2002) .
Immunohistochemistry
Immunostaining was performed on mouse mammary sections with antibodies against TN-W and TN-C as previously described (Scherberich et al., 2004) . Appropriate Alexa red and green secondary antibodies (Molecular Probes) were diluted as recommended by the manufacturer. Images were acquired using a Zeiss fluorescence microscope, a Sony 3CCD camera and Scion Image software. Immunostaining with antia8 integrin was conducted using methods described in Nikolova et al. (1998) .
Western blot analysis
Cells in culture, tissues or culture supernatants were directly solubilized for 5 min at 951C in SDS-PAGE sample buffer, followed by electrophoresis on 6-10% polyacrylamide gels. Proteins were electro-transferred onto PVDF membranes (Millipore). After blocking for 1 h at room temperature in TBS with 0.05% Tween and 3% skim milk powder, membranes were incubated overnight with the appropriate primary antibody, washed, and then incubated for 1 h with the appropriate secondary antibody coupled to HRP (1/10 000). Specific staining was revealed using ECL kits (Amersham).
Adhesion and migration assay
Cell motility was tested in 8-mm-pore polycarbonate membrane Transwell chambers (Costar) essentially as described by the manufacturer. The underside of the polycarbonate membranes was coated with 40 mg/ml of rat tail collagen type I (Upstate Biotechnology), fibronectin (purified from horse serum as described in Fischer et al., 1997) , recombinant mouse TN-W or recombinant mouse TN-C (both as described in Scherberich et al., 2004) . 4T1 and HC11 cells were resuspended in serum-free medium and 100 000 cells were added to the top chamber. Serum-free medium was added to the bottom chamber, and cells were allowed to migrate for 20 h (HT11 and 4T1 cells) or 36 h (NIH/3T3 cells). Cells were scraped off the top of the membrane using a cotton swab. Cells that migrated across the membrane were fixed in 3.7% formaldehyde and stained with 1% crystal violet. Cells were counted under a microscope in four different high-power fields in duplicate wells in at least two independent experiments. T-tests to determine significant differences in the number of cells migrating across the filters were performed using Microsoft Excel.
NIH/3T3 cells were transfected with a full-length a8 integrin cDNA in pcDNAI kindly provided by Lynn Schnapp et al. (1998) . After 1 day, a8-transfected and vector-only transfected cells were harvested and used for short-term adhesion assays as described before (Scherberich et al., 2004) . The same cells were also used for transfilter migration assays as described above.
